The development of an effective synthetic route of rilpivirine

BACKGROUND: Rilpivirine (RPV) was approved by the U.S. FDA (Food and Drug Administration) in 2011 to treat individuals infected with human immunodeficiency virus 1 (HIV-1). Significantly, rilpivirine is three fold more potent than etravirine. Once-daily, it is used with a low oral dose (25 mg/tablet...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Tao, Yang, Jiapei, Zhou, Zhongxia, Fu, Zhipeng, Cherukupalli, Srinivasulu, Kang, Dongwei, Zhan, Peng, Liu, Xinyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017658/
https://www.ncbi.nlm.nih.gov/pubmed/33810807
http://dx.doi.org/10.1186/s13065-021-00749-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017658/
https://www.ncbi.nlm.nih.gov/pubmed/33810807
http://dx.doi.org/10.1186/s13065-021-00749-y

Ejemplares similares